Source: Virtual Congress 2020 – Localised non-small cell lung cancer
Disease area: Interstitial lung diseases, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
N. Hirama (Kanagawa, Japan), M. Yamamoto (Kanagawa, Japan), H. Kanaoka (Kanagawa, Japan), T. Muraoka (Kanagawa, Japan), K. Somekawa (Kanagawa, Japan), M. Hirata (Kanagawa, Japan), T. Kamimaki (Kanagawa, Japan), S. Ikeda (Kanagawa, Japan), S. Kubo (Kanagawa, Japan), U. Ryouta (Kanagawa, Japan), S. Manabe (Kanagawa, Japan), M. Kudou (Kanagawa, Japan), T. Kaneko (Kanagawa, Japan). A retrospective analysis of risk factors for Durvalumab related interstitial lung disease after chemoradiotherapy in Stage III NSCLC. 1638

Member's Comments

No comment yet.

Related content which might interest you: Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Preoperative biopsy risk for recurrence?: A retrospective study of risk factors for recurrence of stage 1A non-small cell lung cancer Source: International Congress 2017 – How to reach peripheral lesions: (radial EBUS, CLE, navigation, etc.) and treat airleaks Year: 2017 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Retrospective assessment of non small cell lung cancer stage IIIA-IIIB, treated with neoadjuvant chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Unsuspected N2 disease: A retrospective analysis comparing survival in patients with suspected N2 disease in non-small cell lung cancer Source: International Congress 2017 – Thoracic surgery Year: 2017 Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Phase II study of cisplatin-vinorelbine sequenced by gemcitabine-vinorelbine in patients with unresectable non-small-cell lung cancer (NSCLC): preliminary results Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Comparative evaluation of resectability, postoperative morbidity and mediastinal downstaging after cisplatin-based chemoinduction versus radiochemoinduction for stage III non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 214s Year: 2003 Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer Source: Eur Respir J, 51 (5) 1702431; 10.1183/13993003.02431-2017 Year: 2018 A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominator Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008 Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001